Comparison of Neoadjuvant Chemotherapy Plus Interval Debulking Surgery and Primary Debulking Surgery in Patients with Stage III and IV Ovarian Carcinoma: A Multicenter Real Life Experience

被引:0
|
作者
Yilmaz, Mukaddes [1 ]
Basak, Mustafa [2 ]
Ozyukseler, Deniz Tataroglu [3 ]
Yildirim, Mahmut Emre [4 ]
Arik, Zafer [5 ]
Salman, Mehmet Coskun [6 ]
Gultekin, Murat [6 ]
Akgor, Utku [7 ]
Inci, Bediz Kurt [8 ]
Gurler, Fatih [9 ]
Yucel, Kadriye Bir [10 ]
Savas, Gozde [10 ]
Onan, Mehmet Anil
Sunar, Veli [12 ]
Meydanli, Mehmet Mutlu [11 ,13 ]
Yazici, Ozan
Ozet, Ahmet [10 ]
机构
[1] Sivas Cumhuriyet Univ, Dept Med Oncol, Fac Med, Sivas, Turkiye
[2] Gazi Osman Pasa Univ, Dept Med Oncol, Fac Med, Tokat, Turkiye
[3] Fethi Sekin State Hosp, Dept Med Oncol, Elazig, Turkiye
[4] Dr Lutfi Kirdar Kartal Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye
[5] Hacettepe Univ, Dept Med Oncol, Canc Inst, Ankara, Turkiye
[6] Hacettepe Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[7] Ankara Numune Training & Res Hosp, Dept Gynecol Oncol, Ankara, Turkiye
[8] Kirsehir Training & Res Hosp, Dept Med Oncol, Kirsehir, Turkiye
[9] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hos, Dept Med Oncol, Ankara, Turkiye
[10] Gazi Univ, Dept Med Oncol, Fac Med, Ankara, Turkiye
[11] Gazi Univ, Dept Gynecol Oncol, Fac Med, Ankara, Turkiye
[12] Aydin Ataturk State Hosp, Dept Med Oncol, Aydin, Turkiye
[13] Med Pk Hosp, Dept Gynecol Oncol, Gaziantep, Turkiye
关键词
Interval debulking; neoadjuvant chemotherapy; ovarian carcinoma; primary debulking; CANCER; SURVIVAL; CYTOREDUCTION; OUTCOMES;
D O I
10.5505/tjo.2023.3883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
OBJECTIVE The aim of the study is to compare treatment outcomes of the patients with federation of gynecology and obstetrics stages III and IV ovarian carcinomas, who underwent interval debulking surgery after neoadjuvant chemotherapy (NACT), and patients who underwent adjuvant chemotherapy after primary debulking surgery (PDS). METHODS Patients from four centers (n=183) were retrospectively evaluated. Of the patients, 91 (50%) were in the PDS group and 92 (50%) in the NACT group. RESULTS In the NACT group patients have advanced age, poor performance status, high levels of CA125, and advanced disease stage compared with the PDS group (p<0.050). Of the patients receiving NACT, 14 (15%) had a complete response, and 68 (74%) had a partial response. The R0 rate was higher in the PDS group (p=0.018). In univariate analysis, poor prognostic factors affecting OS were NACT in the treatment protocol (p<0.001), poor performance status (p<0.001), advanced age (<70 vs. >= 70, p=0.002), advanced clinical stage (p=0.042), and localization of the tumor with the largest diameter outside the omentum and ovary at the time of diagnosis (p=0.029). In the multivariate analysis, the presence of NACT (HR: 2.30, 95% CI: 1.25-4.23, p=0.007) and poor performance (HR: 2.52, 95% CI: 1.18-5.10, p=0.017) were independent poor prognostic factors for OS. CONCLUSION In the study, OS was better in the PDS group than in the NACT group. This result was thought to be associated with the NACT group having more disadvantageous characteristics (advanced age, poor performance, high CA125 level, advanced stage, etc.).
引用
收藏
页码:323 / 332
页数:10
相关论文
共 50 条
  • [41] Comparison of platinum-based neoadjuvant chemotherapy and primary debulking surgery in patients with advanced ovarian cancer
    Sayyah-Melli M.
    Zonoozi G.K.
    Hashemzadeh S.
    Esfahani A.
    Ouladehsahebmadarek E.
    Shobeiry M.J.
    Garabaghi P.M.
    Ramin A.
    The Journal of Obstetrics and Gynecology of India, 2013, 63 (6) : 405 - 409
  • [42] Debulking Surgery in Advanced Epithelial Ovarian Cancer: Interval or at the End of Neoadjuvant Chemotherapy?
    F. Cantu-de Leon, D.
    Gallardo-Alvarado, L.
    Salcedo-Hernandez, R.
    Ramirez, R.
    Perez-Montiel, D.
    Onate-Ocana, L.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S86 - S86
  • [43] Delays from neoadjuvant chemotherapy to interval debulking surgery and survival in ovarian cancer
    Liu, Ying L.
    Zhou, Qin C.
    Iasonos, Alexia
    Filippova, Olga T.
    Chi, Dennis S.
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger
    Broach, Vance
    OCearbhaill, Roisin
    Konner, Jason A.
    Aghajanian, Carol A.
    Long, Kara
    Tew, William
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (10) : 1554 - 1561
  • [44] Laparoscopic interval debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer
    Nitecki, R.
    Melamed, A.
    Boruta, D. M., II
    del Carmen, M. G.
    Clark, R. M.
    Growdon, W. B.
    Goodman, A.
    Schorge, J. O.
    Rauh-Hain, J. A.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 125 - 125
  • [45] Primary debulking surgery versus neoadjuvant chemotherapy in elderly patients with epithelial ovarian cancer
    Xu, Z.
    Justiniano, C. F.
    Fleming, F. J.
    Boscoe, F. P.
    Schymura, M. J.
    Rubinsak, L. A.
    Morrow, G.
    Minasian, L.
    Temkin, S. M.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 78 - 78
  • [46] Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals
    Kobal, Borut
    Noventa, Marco
    Cvjeticanin, Branko
    Barbic, Matija
    Meglic, Leon
    Herzog, Marusa
    Bordi, Giulia
    Vitagliano, Amerigo
    Saccardi, Carlo
    Skof, Erik
    RADIOLOGY AND ONCOLOGY, 2018, 52 (03) : 307 - 319
  • [47] Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
    Liu, Ying L.
    Filippova, Olga T.
    Zhou, Qin
    Iasonos, Alexia
    Chi, Dennis S.
    Zivanovic, Oliver
    Sonoda, Yukio
    Gardner, Ginger J.
    Broach, Vance A.
    O'Cearbhaill, Roisin E.
    Konner, Jason A.
    Aghajanian, Carol
    Roche, Kara Long
    Tew, William P.
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2020, 31 (01)
  • [48] The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with advanced ovarian cancer
    Goncalves, M. D.
    Vitarello, J.
    Zhou, Q.
    Iasonos, A.
    Halpenny, D.
    Mueller, J. J.
    Zivanovic, O.
    Cadoo, K. A.
    Konner, J.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 103 - 103
  • [49] Progression-free survival and overall survival in patients diagnosed with stage III/IV ovarian cancer and treated with primary surgery or neoadjuvant chemotherapy with or without delayed debulking surgery
    Russell, M.
    Twigg, J.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S101 - S101
  • [50] Primary Cytoreductive Surgery Versus Interval Debulking Surgery Following Neoadjuvant Chemotherapy in Epithelial Ovarian Cancer: An Institutional Review
    Zeeshanuddin Ahmad
    Amar Jain
    Nikhil Mehta
    Elroy Saldanha
    Dhruv Patel
    Sanjay M. Desai
    Indian Journal of Gynecologic Oncology, 2019, 17